IL4R and conjunctivitis: In addition, we identified IL-4Rα–augmented pathways by comparing blockade of IL-4Rα with isotype control, which may underlie the partial efficacy in this model and could possibly represent candidate mediators of the paradoxically increased frequency of conjunctivitis following dupilumab in patients with AD.